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Abstract: The suppressor of cytokine 
signaling (SOCS) proteins are negative 
regulators of the JAK/STAT pathway 
activated by pro-inflammatory cytokines, 
including the tumor necrosis factor- (TNF-
). SOCS3 is also implicated in 
hypertriglyceridemia associated to insulin-
resistance (IR). Proprotein Convertase 
Subtilisin Kexin Type 9 (PCSK9) levels are 
frequently found to be positively correlated 
to IR and plasma very low-density 
lipoprotein-triglycerides (VLDL-TG) 
concentrations. The present study aimed to 
investigate the possible role of TNF- and 
JAK/STAT pathway on de novo lipogenesis 
and PCSK9 expression in HepG2 cells. TNF-
 induced both SOCS3 and PCSK9 in a 
concentration-dependent manner. This 
effect was inhibited by transfection with 
siRNA anti-STAT3, suggesting the 
involvement of the JAK/STAT pathway. 
Retroviral overexpression of SOCS3 in 
HepG2 cells (HepG2SOCS3) strongly inhibited 
STAT3 phosphorylation and induced 
PCSK9 mRNA and protein, with no effect on 
its promoter activity and mRNA stability.  
Consistently, siRNA anti-SOCS3 reduced 
PCSK9 mRNA levels while an opposite effect 
was observed with siRNA anti-STAT3. In 
addition, HepG2SOCS3 express higher mRNA 
levels of key enzymes involved in the de novo 
lipogenesis, such as fatty-acid synthase 
(FAS), stearoyl-CoA desaturase, and apo-B. 
These responses were associated with 
significant increase of SCD-1 protein, 
activation of SREBP-1, accumulation of 
cellular TG, and secretion of apoB. 
HepG2SOCS3 shows lower phosphorylation 
levels of IRS-1 Tyr896 and Akt Ser473 in 
response to insulin. Finally, insulin 
stimulation produced an additive effect with 
SOCS3 overexpression, further inducing 
PCSK9, SREBP-1, FAS and apoB mRNA. In 
conclusion, our data candidate PCSK9 as a 
gene involved in lipid metabolism regulated 
by pro-inflammatory cytokine TNF-, in a 
SOCS3 dependent manner.   
 http://www.jbc.org/cgi/doi/10.1074/jbc.M115.664706The latest version is at 
JBC Papers in Press. Published on December 14, 2015 as Manuscript M115.664706
 Copyright 2015 by The American Society for Biochemistry and Molecular Biology, Inc.
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INTRODUCTION 
The family of suppressor of cytokine signaling 
(SOCS) consists of eight members (SOCS-1 to 
SOCS-7 and CIS) all sharing a central SH2 
domain and a C-terminal SOCS box. Expression 
of CIS, SOCS-1, SOCS-2 and SOCS-3 is induced 
by various cytokines, including IL-6 and TNF- 
(1), and has been implicated in the negative 
regulation of several pathways, particularly the 
Janus kinase (JAK)-Signal Transducer and 
Activator of Transcription (STAT) one (2). 
SOCS proteins are highly and selectively 
induced in a tissue-specific manner by a diverse 
range of stimuli, other than the classical 
activators of the JAK/STAT pathway, including 
insulin (3), leptin (4), and resistin (5). In obesity, 
the expression of SOCS proteins is elevated in a 
variety of tissues that are vital for regulating 
fatty-acid (FA) metabolism and insulin 
sensitivity. For instance, SOCS1 and SOCS3 are 
upregulated in the liver of obese diabetic db/db 
mice and other insulin-resistance (IR) models, 
such as ob/ob mice and mice fed high-fat diet 
(6,7). The functional role of SOCS3 on hepatic 
steatosis and hyperlipidemia was also 
demonstrated by using SOCS antisense 
approach. The latter reduced in db/db mice the 
elevated hepatic lipid content and plasma 
triglycerides close to the normal observed in 
control mice (7). Furthermore, liver of morbidly 
obese subjects exhibits higher expression of 
SOCS3 protein and attenuated JAK/STAT 
signaling, resulting in enhanced sterol regulatory 
element binding protein-1c (SREBP-1c) 
transcriptional activity, a key regulator of de 
novo lipid biosynthesis (8). This evidence might 
suggest that the inhibition of JAK/STAT 
pathway by SOCS3 is mechanistically related to 
the development of hepatic IR and dyslipidemia 
in humans. 
Proprotein Convestase Subtilisin Kexin Type 
9 (PCSK9) belongs to the proprotein convertase 
family (9). Genetic and, more recently, 
pharmacological studies have clearly 
demonstrated its involvement in the regulation of 
low-density lipoprotein cholesterol (LDL) levels 
by inducing the degradation of the LDL receptor 
(LDLR) in a manner independent from its 
proteolytic activity (10-13). Similarly to the 
genes involved in the regulation of the 
cholesterol homeostasis, i.e. hydroxyl-methyl-
glutaryl CoA reductase and synthase and the 
LDLR, PCSK9 is under the control of the 
SREBP-2 (14). For this reason, the 
pharmacological activation of the SREBP 
pathway by HMG-CoA reductase inhibitors, 
statins, induces PCSK9 both in experimental and 
clinical settings (15-17). While SREBP-1a and 
SREBP-1c preferentially activate genes involved 
in the synthesis of fatty acids and triglycerides, 
their homologous SREBP-2 preferentially 
transcribes for genes involved in the cholesterol 
biosynthetic pathway (18,19). To this regard, 
PCSK9 appears to be regulated by both SREBP-
2 and SREBP-1c (14,20), where the latter 
mediating the induction of PCSK9 in response to 
insulin (14,21-23). The involvement of SREBP-
1c in the regulation of PCSK9 levels has also 
been observed in humans, where PCSK9 levels 
positively correlated with IR, liver steatosis and 
very low density lipoprotein-triglycerides 
(VLDL-TG) (24).  
This evidence suggests that, although PCSK9 
is an important regulator of LDL-C levels, it 
could be also implicated in the homeostasis of 
TG-rich lipoproteins. It is, indeed, of interest that 
the association between plasma PCSK9 and 
LDL-C is weak and has been estimated to 
account for only the 7% of the variations in LDL-
C (25), while PCSK9 levels are more 
significantly associated with plasma 
concentrations of TG, glucose and insulin 
(21,25-27). Based on these premises, the present 
study aimed to investigate the possible role of 
TNF- and JAK/STAT pathway on de novo 
lipogenesis and PCSK9 expression in human 
HepG2 cell line.  
 
EXPERIMENTAL PROCEDURES 
Cell cultures - The Human hepatocellular liver 
carcinoma cell line, HepG2, was cultured in 
10%FCS/MEM supplemented with penicillin 
(10,000 U/ml), streptomycin (10 mg/ml), 
nonessential amino acids and sodium pyruvate. 
For the experiments, cells were incubated with 
MEM containing either 10% of lipoprotein 
plasma deprived serum (LPDS) or 10% Fetal 
Calf Serum (FCS), as indicated in the figures 
legend. 
Reagents and antibodies - MEM, trypsin EDTA, 
penicillin, streptomycin, nonessential amino acid 
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solution, FCS, disposable culture flasks and petri 
dishes were from Euroclone (Pero, Milan, Italy), 
and filters were from Millipore (Billerica, MA). 
Molecular weight protein standards were from 
BIO-RAD Laboratories (Hercules, CA). SDS, 
TEMED, ammonium persulfate, glycine, and 
acrylamide solution (30%T, 2.6%C) were 
obtained from BIO-RAD Laboratories. BCA 
assay for determination of protein concentrations 
was purchased from Thermo Fischer Scientific 
(Waltham, MA). [14C]-Acetate were from 
Amersham (Cologno Monzese, Milan, Italy). 
Recombinant insulin, Tumor Necrosis Factor- 
(TNF-) and bovine serum albumin (BSA) were 
purchased from SIGMA-Aldrich (Milan, Italy). 
STAT3 inhibitor, MD77, was kindly provided by 
Prof. Daniela Barlocco (Università degli Studi di 
Milano, Milan, Italy) [31]. The JAK inhibitor 
JAK1 was purchased from Millipore (Millipore, 
Milan, Italy). Actinomycin D was purchased 
from Abcam (Cambridge, UK) and fatostatin 
hydrobromide and 25-hydroxycholesterol (25-
OH cholesterol) from SIGMA-Aldrich (Milan 
ITALY). For Western Blot (WB) analysis, the 
following antibodies were used: anti-PCSK9 and 
anti SREBP-2 (Cayman, Tallinn, Estonia), anti-
α-tubulin (SIGMA-Aldrich), anti-pAKT 
(Millipore); anti-AKT and anti-SOCS3 (Cell 
Signalling Tecnology, Danver, MA); anti-
pSTAT3, anti-insulin receptor substrate (pIRS-1) 
and anti- stearoyl-CoA desaturase (SCD-1) and 
anti-hepatocyte nuclear factor (HNF)-1α 
(Abcam, Cambridge, UK); anti-STAT3 and 
SREBP-1 (Santa-Cruz Biotechnology, Santa 
Cruz, CA); anti-mouse and anti-rabbit 
peroxidase-conjugated secondary antibodies 
(Jackson ImmunoResearch Lab; 
Cambridgeshire, UK).  
Animals - Four-week-old male ob/ob mice and 
their lean, wild-type male C57BL/6J controls 
were purchased from Charles River (Calco, 
Italy). In compliance with the Principles of 
Laboratory Animal Care (NIH publication 86-
23), mice were housed at constant room 
temperature (23°C) in a 12-hour light/dark cycle 
(7 a.m. to 7 p.m) receiving standard chow and 
water ad libitum. Mice were sacrificed at 
fourteen weeks of age in the fasted state. 
Generation of human SOCS3 expression 
construct and retroviral infection in HepG2 cells 
- Full-length human SOCS3 (accession no. 
003955) was generated by polymerase chain 
reaction (PCR) using the following primers: 5’-
CGGGATCCATGGTCACCCACAGCAAGTT
TCC-3’ and 5’-CGCTCGAGTTAAAGCGGG 
GCATCGTACTGG-3’and the Expand High-
Fidelity PCR System (Roche Diagnostics, S.p.A, 
Monza, Italy). The sequence of the polymerase 
chain reaction generated construct was 
confirmed by sequencing (Primm, Milan, Italy). 
Retroviral expression plasmid was then 
constructed using the pBM-IRES-PURO (28) 
expressing the puromycin resistance gene as a 
selectable second cistron gene, generated from 
the original pBM-IRES-EGFP, generously 
provided by Garry P. Nolan (Stanford 
University, Stanford, CA). Retroviral infections 
of HepG2 were performed as previously 
described (28,29). A polyclonal population of 
HepG2 control and SOCS3 overexpressing cells 
have been than selected with 10 μg/ml of 
puromycin. 
Transfection of siRNA - ON-TARGET plus 
SMART pool siRNA directed to STAT3 and 
SOCS3 or scramble control were purchased from 
DharmaconTM (Carlo Erba Reagents, Milan, 
Italy). Transfections were performed as 
previously described using SilentFectTM Lipid 
Reagent (BIO-RAD laboratories, Hercules, CA) 
according to the manufacturer’s protocol (30,31). 
HepG2 cells were seeded at a density of 
6×105/well (6 well tray) the day before the 
transfection in completed medium. Cells were 
then transfected with 20 nM of siRNA for 48h 
then the medium replaced with MEM containing 
5%LPDS ± TNF- for an additional 24h before 
performing the quantitative (q)PCR or WB 
analysis.   
Synthesis of total cholesterol - Cholesterol 
biosynthesis was estimated by measuring the 
incorporation of [14C]-Acetate into cellular 
cholesterol, as previously described (32). 
Evaluation of intracellular TG and Cholesterol 
levels - Total cellular lipids were extracted with 
hexane/isopropanol 3:2 and TG and Cholesterol 
contents were determined with enzymatic assays 
(HORIBA ABX, Montpellier, France). 
ELISA assay. Conditioned media was cleared by 
centrifugation (13,000 rpm for 10 min.) and store 
at -20°C. The amount of apolipoprotein (apo) B 
(Vinci-Biochem, Firenze, Italy) and PCSK9 
(R&D System, Minneapolis, MN) was then 
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quantified by using the ELISA assays according 
to manufacturer’s instructions. The values were 
normalized with total cell protein contents, 
extracted from the cell monolayer, determined by 
BCA assay (Thermo Fischer Scientific).  
Luciferase reported promoter activities assay - 
The plasmid pGL3-PCSK9-D4 contains the 5′ 
flanking region of the PCSK9 gene from -440 to 
-94, relative to the ATG start codon as previously 
described (33). To measure the PCSK9 promoter 
activity, HepG2 cells were seeded in 48 well 
plates at a density of 8×105 cells per well. On the 
next day, cells were transiently transfected with 
pGL3-PCSK9-D4 plasmids with turbofect 
reagent (Carlo Erba Reagents) and, 48h post 
transfection, cells were incubated with serum-
free medium in the presence or absence of insulin 
(10-7M) for an additional 24h. Luciferase 
activities were measured by using Neolite 
reagent (Perkin Elmer, Milan, Italy) according to 
manufacturer’s instructions. pCMV-β vector, 
encoding for β-galactosidase, (Clontech Lab., 
mountain View, CA) was cotransfected as 
internal control. β-galactosidase activity was 
assayed as described (34). Luciferase activity 
was normalized to the β-galactosidase activity of 
the cotransfected pCMV-β construct. 
RNA preparation and quantitative real time 
PCR- Total RNA was extracted with the iScript 
Sample Preparation Buffer (BIO-RAD 
laboratories) cDNA synthesis preparation 
reagents (BIO-RAD laboratories) according to 
manufacturer’s instructions. Reverse 
transcription-polymerase first-strand cDNA 
synthesis was performed by using the iScript 
cDNA synthesis Kit (BIO-RAD laboratories). 
Quantitative real time PCR (qPCR) was then 
performed by using the Kit Thermo SYBR 
Green/ROX qPCR Master Mix (Carlo Erba 
Reagents) and specific primers for selected 
genes. Primer sequences used for qPCR analysis 
are shown in Table 1. The analyses were 
performed with the ABI Prism® 7000 Sequence 
Detection System (Applied Biosystems; Life 
Technologies Europe BV, Milan, Italy). PCR 
cycling conditions were as follows: 94°C for 
3min, 40 cycles at 94°C for 15s, and 60°C for 
1min. Data were expressed as Ct values and used 
for the relative quantification of targets with the 
ΔΔCt calculation. 
Western Blot Analysis - Total cytosolic protein 
extracts of HepG2 and HepG2SOCS3, were 
obtained by collecting cells in 150 μl of 
Mammalian Protein Extraction Reagents 
(Thermo Fisher Scientific) containing a cocktail 
of protease and phosphatase inhibitors (Roche 
Diagnostics). Twenty µg of proteins and a 
molecular mass marker (Novex® Sharp Protein 
Standard, InvitrogenTM; Life Technologies 
Europe BV) were separated on 4-12% sodium 
dodecylsulfate-polyacrylamide gel (SDS-PAGE; 
Novex® NuPAGE® 4-12% Bis-Tris Mini Gels, 
InvitrogenTM; Life Technologies) under 
denaturing and reducing conditions. Proteins 
were then transferred to a nitrocellulose 
membrane by using the iBlotTM Gel Transfer 
Device (InvitrogenTM; Life Technologies). The 
membranes were washed with Tris-Buffered 
Saline-Tween 20 (TBS-T) and non-specific 
binding sites were blocked in TBS-T containing 
5% (BSA; Sigma-Aldrich) for 90 min at RT. The 
blots were incubated overnight at 4°C with a 
diluted solution (5% BSA or non-fat dried milk) 
of the following human primary antibodies: anti-
PCSK9 (1:100); anti SREBP-2 (1:200) anti-
pAKT, (1:100); anti-AKT (1:1,000); anti-
pSTAT3 (1:10,000); anti-pIRS-1 (1:5,000); anti-
SCD-1 (1:500); anti-STAT3 (1:1,000); anti-
SREBP-1a (1:500); anti-SOCS3 (1:100); anti-
HMG-CoA reductase (1:500); anti HNF-1α 
(1:1,000)and anti-α-tubulin (1:2,000). 
Membranes were washed with TBS-T and then 
exposed for 90 min at RT to a diluted solution 
(5% non-fat dried milk) of the secondary 
antibodies. Immunoreactive bands were detected 
by exposing the membranes to ClarityTM 
Western ECL chemiluminescent substrates (Bio-
Rad Laboratories) for 5 min and images were 
acquired with a ChemiDocTM XRS System 
(Bio-Rad Laboratories). Densitometric readings 
were evaluated using the ImageLabTM software 
as previously described. The values of the 
phosphorylated proteins were normalized to 
those of the corresponding constitutive forms to 
express arbitrary units of relative expression. 
Analysis of the data – Statistical analysis was 
performed using the Prism statistical analysis 
package version 6.0 (GraphPad Software, San 
Diego, CA). Data are given as mean ± SD of 
three independent experiments. When possible, 
p-values were determined by Student’s t-test. 
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Otherwise, differences between treatment groups 
were evaluated by 1-way ANOVA. A probability 
value of p<0.05 was considered statistically 
significant. 
 
RESULTS 
TNF- induces SOCS3 and PCSK9 in HepG2 
cells - Release of pro-inflammatory cytokines, 
such as TNF-α and IL-6, from adipocytes of 
obese subjects with IR, has been shown to 
activate the JAK/STAT pathway at the hepatic 
levels and inducing, either directly or indirectly, 
the transcription of different target genes 
including SOCS proteins (6,7). In agreement 
with these observations, we found that the 
incubation of hepatic cell line HepG2 with TNF-
α induced the expression of SOCS3 mRNA in a 
time- and concentration-dependent manner 
(Figure 1A), reaching the maximal induction 
after 24h incubation at the concentration of 10 
ng/ml. This latter resulted in three-fold induction 
of SOCS3 protein, evaluated by WB analysis 
(Figure 1A). Under the same experimental 
conditions, TNF- induced both PCSK9 mRNA, 
although to lower extent (Figure 1B), and  
PCSK9 protein (+41%), as determined by WB 
analysis (Figure 1B). Transfection of HepG2 
cells with specific siRNA significantly down-
regulated protein expression of STAT3 and 
SOCS3 (Figure 1C). siRNA STAT3 completely 
blocked the induction of SOCS3 by TNF- 
(Figure 1D). A similar effect was observed on the 
expression levels of PCSK9, where siRNA to 
either SOCS3 or STAT3 blocked the effect of 
TNF- (Figure 1E). These results suggest the 
possibility that TNF- induces PCSK9 by 
inducing the SOCS3 expression.   
SOCS3 overexpression induces PCSK9 in 
HepG2 - To further investigate the role of 
SOCS3 on PCSK9 expression, we generated a 
retrovirally transduced HepG2 cell line with a 
plasmid encoding human SOCS3 (HepG2SOCS3). 
After puromycin selection, the mRNA and 
protein overexpression of exogenous human 
SOCS3, were evaluated by qPCR and WB 
analyses, respectively. HepG2SOCS3 cells were 
compared with HepG2 transduced with empty 
retroviral vector encoding only the puromycin 
resistance gene. As shown in Figure 2A, 
retroviral transduction determined 
approximately 90-fold induction of mRNA of 
SOCS3 that translated into a 70%  increase of 
protein SOCS3 (Figure 2B). The overexpression 
of SOCS3 abrogated basal STAT3 
phosphorylation state (Figure 2C). 
HepG2SOCS3 cells show higher levels of 
PCSK9 mRNA (3.48±0.35 fold, Figure 2D) and 
increased amount of cellular and secreted PCSK9 
(1.53 fold and 2.18±0.38 fold respectively; 
Figure 2E and 2F). Since SOCS3 has been shown 
to be up-regulated in animal models of obesity 
(6), we then evaluated the mRNA levels of 
PCSK9 and SOCS3 in the liver of ob/ob and 
wild-type C57BL/6 control mice. The ob/ob mice 
expressed higher levels of SOCS3 (6.46±4.8 
fold) and this condition was associated with a 
significant induction of PCSK9 (2.03±1.54 fold) 
(Figure 2G and 2H). 
The inhibition of SOCS3 and STAT3 by 
siRNA resulted in an opposite effect on PCSK9 
mRNA levels, with a significant reduction after 
transfection with siRNA SOCS3 and an 
induction with siRNA STAT3 (Figure 2I).  
We then investigated the effect of SOCS3 on 
PCSK9 promoter activity in HepG2 and 
HepG2SOCS3 transfected with the luciferase 
reporter construct pGL3-PCSK9-D4 (33). This 
plasmid contains the 5 ′ flanking region of the 
PCSK9 gene, from nt -440 to -94 (relative to the 
ATG start codon), in front of the luciferase 
coding sequence. The relative luciferase activity 
of the PCSK9 promoter was not affected by the 
expression of SOCS3 in HepG2 cells (Figure 
2L).  A similar response was observed by using 
the D4 construct containing the mutation of sterol 
regulatory element (SRE), while the mutation of 
HNF-1 site determined a significant increase of 
the promoter activity in HepG2SOCS3 cells, 
although the overall transcriptional activity was 
almost abolished (Figure 2L). 
To further investigate the effect of SOCS3 on 
the PCSK9 mRNA induction, we determined the 
involvement of the SREBP factors by incubating 
HepG2 with 25-OH cholesterol (inhibitor of both 
SREBP-1 and SREBP-2) (32) or fatostatin (a 
more selective inhibitor of SREBP-1) (35). As 
shown in Figure 3A, 25-OH cholesterol, 
completely downregulated the PCSK9 mRNA 
levels in both HepG2 and HepG2SOCS3. On the 
contrary, fatostatin affected exclusively the 
induction of PCSK9 in HepG2SOCS3 (Figure 3B).  
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SOCS3 overexpression induced the processing 
from the precursor to the active form of SREBP-
1 (Figure 3C). The activation of SREBP-2 was 
inhibited, with the accumulation of its precursor 
and a reduction of the active form (Figure 3C). In 
addition, HNF-1α protein (+54%) and mRNA 
levels (2.87±0.98 fold) were significantly 
induced in SOCS3 overexpressing cells (Figure 
3C and 3D). The incubation with the 
transcriptional activity inhibitor, actinomycin D, 
showed that in HepG2SOCS3 the stability of 
PCSK9 mRNA was not affected compared to 
HepG2 (Figure 3E). Taken together, these results 
suggest that the PCSK9 induction in response to 
SOCS3 overexpression is mainly mediated by a 
transcriptional-regulated process. 
Pharmacological inhibition of JAK/STAT 
pathway induces PCSK9.  To further investigate 
the effect of STAT3 inhibition on PCSK9 
expression, HepG2 cells were incubated with 
non-toxic concentration of STAT3-inhibitor 
MD77 (Figure 4) (36). Incubation of HepG2 cells 
for 48h with 10-7M MD77, determined a very 
similar cellular responses than those observed 
with SOCS3 overexpression. In particular, 
incubation with MD77 induced fatty-acid 
synthase (FAS; 2.93±1.28 fold, Figure 4A), 
PCSK9 (2.06±0.7 fold, Figure 4B), and only 
marginally HMG-CoA reductase (1.58±0.2fold, 
Figure 4C), with a not statistically significant 
reduction of LDLR (-45.3±24.7%, Figure 4D). 
The JAK inhibitor, JAK1, significantly increased 
FAS (1.56±0.05 fold, Figure 4E), PCSK9 
(3.30±0.32 fold, Figure 4F) and HMG-CoA 
reductase (1.49±0.09 fold, Figure 4G), and 
marginally reduced the LDLR (-43.2±24.2%, 
Figure 4H). Consistently with the results with 
HepG2SOCS3, no effect on PCSK9 promoter 
activity was observed after 24h incubation with 
JAK1 (Figure 4I). Taken together, these results 
demonstrate that the inhibition of the JAK/STAT 
pathway induces PCSK9 in HepG2 cells.  
SOCS3 overexpression induces de novo 
lipogenesis in HepG2 cells - Several in vivo 
evidence demonstrated the pivotal role of SOCS3 
and STAT3 on lipid metabolism and SREBP-1 
transcriptional activity (6,7,37). To verify that a 
similar response also occurs in our experimental 
model, we determined the mRNA levels of 
SREBP-1 target genes, such as FAS and SCD-1 
and the levels of apoB. HepG2SOCS3 cells show 
higher mRNA levels of FAS (3.59±0.40 fold, 
Figure 5A) as well as that of SCD-1 gene 
(1.92±0.12 fold, Figure 5B) and protein 
(3.81±0.75 fold; Figure 5C). Together with these 
changes, we observed a significant increment of 
apoB mRNA (4.08±0.41 fold, Figure 5D), and 
protein in the conditioned media (3.47±0.09 fold, 
Figure 5E). Accumulation of intracellular TG 
levels (22.1±7.1μg/mg protein vs. 
38.3±9.1μg/mg protein; Figure 5F) was seen in 
HepG2SOCS3, with no significant changes in total 
cholesterol content (Figure 5G).  
In response to TNF- we observed a significant 
induction ofSCD-1, apoB and FAS mRNA 
levels (2.11±0.43, 1.60±0.33 and 1.39±0.21 fold, 
respectively; Figure 5H-L). These responses 
were reversed in HepG2 cells transfected with 
siRNA STAT3 (Figure 5H-L). Taken together, 
the overexpression of SOCS3 induces the de 
novo lipogenesis and increased apoB production 
in HepG2 cells, effects dependent by STAT3.   
SOCS3 overexpression does not affect the 
cholesterol biosynthesis in HepG2 - A series of 
experiments were performed to determine the 
effect of SOCS3 on genes under the control of 
SREBP-2, such as HMG-CoA reductase and 
LDLR. HMG-CoA reductase mRNA was 
induced in HepG2SOCS3 cells (2.10±0.66 fold, 
Figure 6A); conversely, the LDLR mRNA levels 
were reduced in response to SOCS3 
overexpression (-56%±21.6%, Figure 6B). These 
changes were not associated with significant 
variation of HMG-CoA reductase protein level 
(Figure 6C). The lack of significant changes of 
HMG-CoA reductase was also confirmed by the 
fact that the cholesterol biosynthesis was not 
altered in HepG2SOCS3 cells compared to HepG2 
cells (Figure 6D). 
Effect of SOCS3 overexpression on insulin-
induced PCSK9 expression - To corroborate the 
pathophysiological relevance of our 
observations, we then investigated the effect of 
SOCS3 overexpression on insulin signaling. As 
shown in Figure 7A, in response to insulin (10-7 
M), a significant induction of IRS-1 Tyr896 and 
Akt Ser473 phosphorylations were observed in 
HepG2. Overexpression of SOCS3 (HepG2SOCS3 
cells) resulted in a reduced activation of both 
IRS-1 (Figure 7A) and AKT (Figure 7B) in 
response to insulin. In accordance with previous 
studies (38), ectopic expression of SOCS-3 
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appeared to elevate basal autophosphorylation, 
although this increase was not statistically 
significant. 
Moreover, STAT3 phosphorylation was induced 
in response to insulin in control cells (HepG2), 
while SOCS3 overexpression (HepG2SOCS3) 
determined an abrogation of this response 
(Figure 7C). As previously reported by Costet et 
al (22), the incubation of HepG2 cells with 
insulin (10-7 M), significantly induced both 
PCSK9 secretion and mRNA (Figure 8A and 
8B), and the presence of SOCS3 further up-
regulated the response to insulin at the mRNA 
levels. However, this effect did not translate to a 
further induction of PCSK9 secretion in the 
cultured media, as determined by ELISA assay 
(Figure 8A). Similarly, we observed an additive 
effect of insulin and SOCS3 on the FAS and 
SREBP-1 mRNA levels (Figure 8C and D) with 
no effect on SREBP-2 and HMG-CoA reductase 
levels (Figure 8E and F). 
 
DISCUSSION 
In the present paper, we have tested the 
hypothesis that the inhibition of the JAK/STAT 
pathway by SOCS3 could influence the PCSK9 
levels in hepatic cell line. The rationale of 
performing this study is based on at least four 
previously reported observations: 1) in clinical 
settings, a positive relationships of apoB-
containing lipoproteins and PCSK9 has been 
observed (24-27); 2) SOCS3 overexpression, in 
mice, induces SREBP-1 transcriptional 
activation and de novo lipogenesis (6,7); 3) 
PCSK9 has been shown to be transcriptionally 
regulated by SREBP-1 and SREBP-2 (22,23); 4) 
the adipokine resistin and insulin induce SOCS3 
and PCSK9 expression in cultured cell lines and 
animal models (5,39-41).  
The first novel aspect that we observed was 
the induction of PCSK9 in response to the pro-
inflammatory cytokine TNF-, the same factor 
that efficiently induces SOCS3 and has been 
implicated in chronic-inflammation associated 
with IR (42,43). To study the possible link 
between SOCS3 and PCSK9, we first suppressed 
the expression of SOCS3 by siRNA in HepG2. 
By using this approach, we demonstrated that 
SOCS3 is required for the TNF-α-driven 
induction of PCSK9 In addition, the silencing of 
STAT3 blocked the induction of SOCS3, 
PCSK9, apoB and SCD-1 in response to TNF- 
(Figures 1 and 5). Although the effect of pro-
inflammatory cytokines on genes regulating the 
de novo lipogenesis has been previously 
described (42,44), our data, candidates PCSK9 as 
a gene involved in lipid metabolism regulated by 
pro-inflammatory cytokine TNF-, in a SOCS3 
dependent manner. We then established an 
hepatic cell line stably overexpressing SOCS3, 
the endogenous inhibitor of STAT proteins, and 
consistently found to be up-regulated in the liver 
of genetically- and diet-induced obese animal 
(6,7).  
By WB analysis, we demonstrated that 
SOCS3 overexpression abrogated STAT3 
phosphorylation and thus, the JAK/STAT 
pathway. By using this cellular model, we 
observed a significant induction of both PCSK9 
mRNA and protein. The involvement of both 
JAK and STAT proteins was then confirmed by 
the use of selective pharmacological inhibitors, 
JAK-I and MD77 (36). The suppression of 
STAT3 by siRNA induced PCSK9, while the 
opposite effect was seen after the downregulation 
of SOCS3. In combination with the induction of 
PCSK9, we also observed increased SREBP-1 
processing and a significant up-regulation of the 
key genes involved in the de novo lipogenesis, 
such as FAS and the SCD-1, together with the 
apoB mRNA, apoB secretion and intracellular 
TG. Interestingly, we noticed that PCSK9 was 
up-regulated in the liver of ob/ob mice, together 
with SOCS3, possibly supporting the link 
between these two genes as observed in cultured 
system. However, being regulated STAT3 by a 
large number of cytokines, like IL-6 and TNF- 
(45), further in vivo studies are needed to 
elucidated the possible role of STAT3 in SOCS3-
driven regulation of PCSK9.The consistent and 
very significant induction of apoB secretion, 
confirmed the pivotal role of SOCS3 and the 
related inflammatory pathway, on 
hypertriglyceridemia. In addition, our 
observation suggested a possible involvement of 
PCSK9 on apoB production by hepatic cells 
and/or by the liver of animal models previously 
described (46-48). For instance, the physical 
interaction between PCSK9 and apoB has been 
shown to increase apoB production, possibly 
through the inhibition of intracellular apoB 
degradation (48). Our evidence further delineate 
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the potential link between PCSK9 and apoB by 
demonstrating that the inhibition of the 
JAK/STAT pathway by SOCS3 is a common 
determinant of their increased production and 
secretion. Notably, recent findings suggest that 
PCSK9 may directly induce apoB mRNA levels 
in enterocytes (49). It is, therefore, possible to 
speculate that SOCS3 could activate a positive 
feedback loop by increasing the expression levels 
of PCSK9, which, in turn, determines the 
induction of apoB secretion. 
Previous studies have established the SREBP-
dependent transcriptional activation of PCSK9. 
Indeed, similarly to the LDLR and other 
cholesterol-regulated genes, the proximal region 
of the PCSK9 promoter contains an SRE-1 motif 
(22,50). In addition, two independent studies 
have demonstrated that insulin, by inducing 
SREBP-1c activity, induces PCSK9 both in vitro 
and in vivo (22,41). We confirmed this evidence 
at both mRNA and protein levels, and the 
combination of SOCS3 and insulin determined a 
further induction of de novo lipogenesis genes, 
SREBP-1, and PCSK9, with no additive effect on 
PCSK9 secretion. These results are in agreement 
with previous studies showing that the inhibition 
of STAT proteins by SOCS3 suppresses the 
transcription of SREBP-1 (7). In our study, the 
transcriptional activation of SREBP-1 was 
demonstrated by the induction of key genes 
involved in the lipid synthesis, such as FAS and 
SCD-1, while SREBP-2 appears to be unaffected 
by SOCS3 for at least three reasons. The 
cholesterol biosynthesis was not altered; an 
opposite regulation of two genes mainly 
regulated by SREBP-2 was observed (HMG-
CoA reductase and LDLR); and the processing 
from the precursor to the active form of SREBP-
2 was not induced in response to SOCS3 
overexpression. The involvement of SREBPs 
was then demonstrated by the fact that the 
incubation with 25-OH cholesterol, which 
completely inhibits their activity, abolished 
PCSK9 expression. The contribution of SREBP-
1, over the SREBP-2, in the regulation of PCSK9 
was further corroborated by using fatostatin, a 
selective SREBP-1 inhibitor (35), which 
completely suppressed the PCSK9 mRNA levels 
in HepG2SOCS3. The involvement of HNF-1α, on 
PCSK9 transcriptional regulation has been 
previously demonstrated (33,51). In the present 
study, we cannot exclude the involvement of 
HNF-1α in SOCS3-mediated PCSK9 induction 
since both protein and mRNA were increased. 
Moreover, the luciferase assay with the PCSK9 
promoter region having either HNF-1 or SRE site 
mutated, were drastically suppressed. These data 
suggest a mutual requirement of both SREBP and 
HNF-1α on transcriptional regulation of PCSK9 
(33).      
The effect of SOCS3 on PCSK9 transcription, 
analyzed in HepG2 and HepG2SOCS3 transiently 
expressing the PCSK9 promoter-driven 
luciferase reporters PCSK9-D4 (33), found, 
unexpectedly, that this functional promoter  was 
unresponsive to SOCS3 overexpression (Figure 
2L). These results suggest that the SOCS3 
response sequences could possibly locate 
upstream of the promoter region considered. On 
this regard, it is important to mention that the link 
between JAK/STAT pathway and PCSK9 has 
been previously investigated in the same cell line 
by the use of the cytokine oncostatin M (52). 
Similar to our study, oncostatin M did not affect 
the PCSK9 promoter activity (52). Since 
previous studies have shown that PCSK9 
transcription is controlled through cis regulatory 
elements located in the proximal promoter region 
of the PCSK9 gene where the Sp1 sites and 
HNF1 and SRE-1 are located (23,33,51) we 
utilized also a PCSK9-D4 containing a mutation 
for the HNF responsive element. Under this 
condition, we detected a significant increase of 
the promoter activity in HepG2SOCS3 cells. These 
observation potentially related to the SREBP 
pathway, activated in response to STAT 
inhibition, although the overall activity was very 
low and potentially not responsible for the 
induction of PCSK9 mRNA levels (7). This 
effect was also not confirmed with the incubation 
of the JAK inhibitor, most likely because of the 
minor inhibition of the pathway in comparison to 
the complete block after SOCS3 overexpression.  
We also exclude a SOCS3 effect on mRNA 
stability in the induction of PCSK9, since 
incubation with the transcriptional inhibitor 
actinomycin D did not affect mRNA stability 
compared to HepG2. Hence, additional analysis 
are required to better define the effect of SOCS3 
on the transcriptional regulation of 
PCSK9.Several studies have described the effect 
of SOCS proteins on insulin signaling (1,43,53). 
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Although the observations may differ by the cell 
type and by the time considered, the majority of 
the studies suggests that SOCS proteins control 
insulin action by reducing the expression of  IRS 
proteins (1,43,53). Indeed, in our experimental 
conditions, SOCS3 overexpression reduced both 
IRS-1 and Akt phosphorylation in response to 
insulin. Moreover, insulin stimulation of 
HepG2SOCS3 determined a further induction of 
genes related to de novo lipogenesis (FAS and 
SREBP-1), as well as PCSK9. Although this 
finding has been obtained in in vitro, it is 
conceivable to hypothesize a functional 
contribution of PCSK9 on the 
hypertriglyceridemic condition observed in type 
2 diabetes mellitus and obesity. Indeed, PCSK9 
directly affects the VLDR expression at the 
adipose tissue determining the accumulation of 
visceral adipose tissue in mice (54). For such 
effect, PCSK9 deficient mice show adipocyte 
hypertrophy, enhanced in vivo fatty acid uptake, 
and ex vivo triglyceride synthesis (54).  
In conclusion, in the present study, we 
provided evidence for the JAK/STAT dependent 
expression of PCSK9 in hepatic cell line, 
suggesting the potential molecular basis of the 
direct relationship between PCSK9 and TG 
levels observed in clinical trials (24-27).  
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FIGURE LEGENDS 
FIGURE 1. TNF- induces SOCS3 and PCSK9 in HepG2 cells. A and B) HepG2 cells were seeded 
in MEM/10% FCS and the day after incubated with MEM supplemented with 10% LPDS for 6h and 
24h in the presence or absence of different concentrations of TNF- (0.1, 1 and 10 ng/ml). At the end 
of the incubation, the total RNA was extracted and mRNA levels of SOCS3 and PCSK9 were 
determined by qPCR. Inserts of panels A and B) SOCS3 and PCSK9 protein expression were 
evaluated by WB analysis from total protein extracts of HepG2 cells incubated for 24h with 10 ng/ml 
of TNF-. α-tubulin was used as loading control. C) HepG2 cells were seeded in MEM/10% FCS 
and the day after transfected with siRNA scramble, STAT3 and SOCS3. After 48h, the medium was 
replaced with MEM with 10% LPDS. After an additional 24h, the protein expression of STAT3 and 
SOCS3 and α-tubulin were evaluated by WB analysis. D and E) The cells were incubated under the 
same experimental conditions described for panels A and B, in the presence or absence of 10 ng/ml 
TNF- during the last 24h of incubation in MEM with 10% LPDS. At the end of the incubation, the 
total RNA was extracted and mRNA levels of SOCS3 and PCSK9 were determined by qPCR. 
Differences between treatments were assessed by Student’s t-test and 1-way ANOVA (when 
necessary), *p<0.05; **p<0.01; ***p<0.001.  
 
 
FIGURE 2. SOCS3 overexpression induces PCSK9 in HepG2 cells. A) HepG2 cells were retrovirally 
transduced with empty retroviral vector or encoding for human SOCS3. After puromycin selection, 
the expression of SOCS3 mRNA was evaluated by qPCR in HepG2 and HepG2SOCS3 cultured in 
MEM supplemented with 10% LPDS for 24h. B) Under the same experimental conditions, SOCS3 
expression was determined by WB analysis from total cell lysates using an anti-SOCS3 antibody. 
The membrane was stripped and re-probed with anti--tubulin antibody as loading control. C) WB 
analyses with anti-phospho-STAT3 and anti-STAT3 were performed from the same samples 
described for panel B. D-F) HepG2 and HepG2SOCS3 cells were seeded in MEM/10%FCS and the day 
after incubated with MEM containing 10%LPDS for 24h. D) PCSK9 mRNA was determined by 
qPCR. Intracellular (E) and secreted (F) PCSK9 levels were evaluated by WB analysis and ELISA 
assay, respectively. For the determination of PCSK9 levels with WB analysis the cells were incubated 
for 24h under serum-free condition. G and H) PCSK9 and SOCS3 mRNA expression levels (qPCR) 
were determined from total hepatic RNA of male ob/ob (n=5) and C57BL/6 control mice (n=5). I) 
HepG2 cells were seeded in MEM/10% FCS and the day after transfected with siRNA scramble, 
SOCS3 and STAT3. After 48h, the medium was replaced with MEM with 10% LPDS. After an 
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additional 24h the total RNA was extracted and mRNA levels of PCSK9 were determined by qPCR. 
L) HepG2 and HepG2SOCS3 cells were transfected with pGL3-PCSK9-D4 or pGL3-PCSK9-SREmut 
or pGL3-PCSK9-HNFmut. The day after the transfection the medium was replaced with MEM 
containing 10%LPDS and, after an additional 24h, luciferase activities were determined by Neolite 
reagent. Luciferase activities were normalized to the β-galactosidase activity of the cotransfected 
pCMV- construct. Differences between groups were assessed by Student’s t-test, *p<0.05; **p<0.01. 
 
FIGURE 3. SOCS3-dependent upregulation of PCSK9 mRNA is mainly driven by a transcriptional 
mechanism. A-D) HepG2 and HepG2SOCS3 were seeded in MEM/10%FCS and the day after incubated 
with MEM containing 10%LPDS for 24h in the presence or absence of  25-OH cholesterol (5µM; A) 
or fatostatin (40µM; B). The levels of PCSK9 mRNA were then determined by qPCR. C) The levels 
of SREBP-1, SREBP-2 and HNF-1α were determined by WB analysis. Arrows indicate the active 
and the precursor forms SREBPs. Two different exposure times were utilized for the precursor and 
the active form of SREBP-2 that have been shown in two different panels. D) HNF-1α mRNA levels 
were determined by qPCR; E) HepG2 and HepG2SOCS3 were incubated at the indicated times with 
actinomycin D (5µg/ml) and PCSK9 mRNA determined by qPCR. Differences between treatments 
were assessed by Student’s t-test and 1-way ANOVA (when necessary), *p<0.05 and **p<0.01 
HepG2 vs HepG2SOCS3; §p<0.01 25-OH cholesterol vs untreated; #p<0.01 fatostatin vs untreated. 
 
FIGURE 4. Pharmacological inhibition of JAK/STAT pathway induces PCSK9 in HepG2 cells.  A-
D) HepG2 cells were seeded in MEM/10%FCS and the day after incubated with MEM containing 
10%LPDS for 24h in the presence or absence of the STAT3 inhibitor MD77 (10-7M) or E-H) JAK 
inhibitor JAK1 (10-5M). mRNA levels of FAS (A and E), PCSK9 (B and F), HMG-CoA reductase 
(C and G), and LDLR (D and H) were determined by qPCR. I) HepG2 cells were transfected with 
pGL3-PCSK9-D4 or pGL3-PCSK9-SREmut or pGL3-PCSK9-HNFmut. The day after the 
transfection the medium was replaced with MEM containing 10%LPDS with or without JAK1 (10-
5M) and, after an additional 24h, luciferase activities were determined by Neolite reagent. Luciferase 
activities were normalized to the β-galactosidase activity of the cotransfected pRSV-galactosidase 
construct. Differences between groups were assessed by Student’s t-test. *p<0.05. 
 
FIGURE 5. SOCS3 overexpression induces de novo lipogenesis in HepG2 cells. A, B and D) HepG2 
and HepG2SOCS3 cells were seeded in MEM/10%FCS and the day after incubated with MEM 
supplemented with 10% LPDS for 24h. mRNA levels of FAS, SCD-1, and apoB were evaluated by 
qPCR analysis from total RNA. C) Under the same experimental conditions, the SCD-1 expression 
was determined by WB analysis from total protein extracts. E) HepG2 and HepG2SOCS3 were cultured 
in serum free medium for 24h in the presence or absence of 10-7M insulin, conditioned media was 
than collected and apoB concentrations determined by ELISA assay. F and G) Under the same 
experimental conditions described for panel A, the intracellular TG and cholesterol levels were 
determined in HepG2 and HepG2SOCS3 by using an enzymatic assay. The values were normalized for 
total protein content. H-I) HepG2 cells were seeded in MEM/10% FCS and the day after transfected 
with siRNA scramble and STAT3. After 48h, the medium was replaced with MEM with 10% LPDS 
in the presence or absence of 10 ng/ml TNF-. After an additional 24h, the total RNA were extracted 
and mRNA levels of SCD-1, apoB and FAS were determined by qPCR.  Differences between HepG2 
and HepG2SOCS3 were assessed by Student’s t-test and 1-way ANOVA (when necessary), *p<0.05; 
**p<0.01; ***p<0.001.  
 
FIGURE 6. Cholesterol biosynthesis is not influenced by SOCS3 in HepG2 cells. A and B) HepG2 
and HepG2SOCS3 cells were seeded in MEM/10%FCS and the day after incubated with MEM 
containing 10%LPDS for 24h and HMG-CoA reductase and LDLR mRNA determined by qPCR (A 
and B, respectively). C) Under the same experimental conditions, HMG-CoA reductase expression 
was assessed by WB analysis from total protein extracts. D) HepG2 and HepG2SOCS3 were cultured 
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in MEM containing 10%LPDS in the presence of [14C]-Acetate. After 48 hours [14C]-Acetate 
incorporation into cellular cholesterol was evaluated. Each bar represents the mean±SD of triplicate 
dishes. Differences between HepG2 and HepG2SOCS3 were assessed by Student’s t-test, *p<0.05. 
 
FIGURE 7. Effect of SOCS3 on insulin-induced IRS-1, Akt and STAT3 phosphorylation.  A-C) 
HepG2 and HepG2SOCS3 were seeded in MEM/10%FCS and starved overnight with serum free 
medium before stimulation with insulin (10-7M) for 5 and 10 min. WB analysis was then performed 
from total protein extracts by using anti-pIRS-1, anti-pAkt, anti-pSTAT3, anti-STAT3 and anti-α-
tubulin antibodies. Densitometric analysis was than evaluated using the ImageLabTM software. 
Differences between groups were assessed by 1-way ANOVA. 
 
FIGURE 8. Effect of insulin on PCSK9 expression in HepG2SOCS3.  A-F) HepG2 and HepG2SOCS3 
cells were seeded in MEM/10%FCS and the day after incubated in serum free medium for 24h in the 
presence or absence of insulin (10-7M). A) At the end of the incubation, the PCSK9 levels in the 
conditioned media were evaluated by ELISA assay, and mRNA levels of PCSK9, FAS, SREBP-1, 
SREBP-2 and HMG-CoA reductase were determined by qPCR (B-F). Differences between groups 
were assessed by 1-way ANOVA. 
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Table 1. Primer sequence utilized for the qPCR analysis. 
 
Human  
Fatty Acid synthase Forward 5’-GCAAATTCGACCTTTCTCAGAAC-3’ 
Fatty Acid synthase Reverse 5’-GGACCCCGTGGAATGTCA-3’ 
HMG-CoA reductase Forward 5’-CTTGTGTGTCCTTGGTATTAGAGCTT-3’ 
HMG-CoA reductase Reverse 5’-GCTGAGCTGCCAAATTGGA-3’ 
SOCS3 Forward 5’-GACCAGCGCCACTTCTTCAC-3’ 
SOCS3 Reverse 5’-CTGGATGCGCAGGTTCTTG-3’ 
SREBP-1 Forward 5’-CGGAACCATCTTGGCAACA-3’ 
SREBP-1 Reverse 5’-GCCGGTTGATAGGCAGCTT-3’ 
SREBP-2 Forward 5’- AGCTGGTCTGTGAAG-3’ 
SREBP-2 Reverse 5’- CGCAATGGGGTCAGC-3’ 
HNF-1α Forward 5’-TGGCGCAGCAGTTCACCCAT-3’ 
HNF-1α Reverse 5’- TGAAACGGTTCCTCCGCCCC-3’ 
LDLR Forward  5’-GTGTCACAGCGGCG-3’ 
LDLR Reverse 5’-CGCACTCTTTGATG -3’ 
PCSK9 Forward 5’-CCTGCGCGTGTCAACT-3’ 
PCSK9 Reverse 5’-GCTGGCTTTTCCGAAACTC-3’ 
SCD-1 Forward 5’-CTATACCACCACCACCACCA-3’ 
SCD-1 Reverse 5’-GGGCATCGTCTCCAACTTAT-3’ 
apoB Forward 5’-GCAGACTGAGGCTACCATGA-3’ 
apoB Reverse 5’-AGGATTGTTCCGAGGTCAAC-3’ 
Mouse  
PCSK9 Forward 5’- AACCTGGAGCGAATTATCCCA-3’ 
PCSK9 Reverse 5’- TTGAAGTCGGTGATGGTGACC-3’ 
 
  
 at U
niversità degli studi di M
ilano on D
ecem
ber 15, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
STAT3 dependent regulation of PCSK9 
17 
 
Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Figure 7 
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Figure 8 
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